SIG
RVNC

Sargent Investment Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sargent Investment Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,732
Closed -$66.1K – 253
2024
Q3 		$66.1K Sell
12,732
-115
-0.9% -$572 0.01% 209
2024
Q2 		$33K Sell
12,847
-48
-0.4% -$164 0.01% 217
2024
Q1 		$63.4K Sell
12,895
-927
-7% -$5.49K 0.01% 195
2023
Q4 		$121K Buy
+13,822
New +$113K 0.03% 202

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Sargent Investment Group's RVNC Position: Q4 2024 in Review

Sargent Investment Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 12,732 shares — an estimated $66.1K sold.

Sargent Investment Group first reported a position in RVNC in Q4 2023 and held it in 4 quarters. The position peaked at $121K in Q4 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Sargent Investment Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Sargent Investment Group sold 12,732 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $66.1K.
  • Sargent Investment Group first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 4 quarters.
  • Sargent Investment Group's Revance Therapeutics, Inc. position peaked at $121K in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Sargent Investment Group's 13F filing for Q4 2024, filed 27 Jan 2025.